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Emerinopathies include diseases caused by EMD gene
mutations localized on chromosome X and encoding
emerin, an integral protein of the nuclear envelope. The
most frequent emerinopathy is the X-linked Emery-
Dreifuss muscular dystrophy (X-EDMD) that was first
reported in the 60ths by Emery and Dreifuss [1]. The
disease is characterized by muscle weakness and wasting
usually with a humeroperoneal distribution in the first
stages, early joint contractures involving Achilles ten-
dons, elbows, neck and the whole spine, and cardiac
involvement featuring conduction defects, arrhythmias,
subsequent cardiomyopathy (usually dilated) and fre-
quently responsible of sudden death. Bione et al. [2]
identified the first mutations of EMD gene encoding
emerin to be responsible of X-EDMD. These mutations
usually lead to absence or reduced level of emerin in
different tissues of affected males including skeletal
muscle, skin, oral mucosa cells and lymphocytes as it is
demonstrated by immunocytochemical and histochem-
ical methods [3,4]. Female carriers exhibit mosaic
expression patterns with usually normal emerin amounts
[3]. These methods may thus be used in the diagnostic
strategy of X-EDMD prior to EMD gene analysis.
In a recent study (unpublished work from the French
network and LBGM) aiming to assess the diagnostic uti-
lity of emerin study by western blot on lymphoblastoïd
cell lines, we looked at EMD mutation rate observed in a
cohort of 269 male and female patients with variable
emerin amounts. In male patients, absence or severe
reduction of emerin (<5%) lead to EMD mutation identi-
fication in all cases, while moderate emerin amount
reduction revealed EMD mutation in 75% of the patients.
Interestingly, in all cases where emerin amounts were
considered as normal, no EMD mutations were found. In
female cases, all cases with emerin moderate or severe
reduction harbored EMD mutation. When emerin is nor-
mal, EMD mutation was found in 58% of female cases.
These results suggest that a diagnostic rate of 100% may
be reached if emerin study by western blot is performed
prior to EMD gene screening in male patients. Moreover,
emerin gene mutations have been rarely observed in rare
cases of isolated cardiac disease [5,6] and limb girdle
muscular dystrophies with cardiac disease and without
joint contractures [7,8].
We reported of a new family with an unusual type of
X-linked fatal isolated cardiac disease. The family
included 9 affected male subjects with early death within
the 4th to 6th decades and suffering from dilated cardio-
myopathy (DCM) with arrhythmias requiring ICD
implantation and or heart transplantation in some cases.
Two surviving brothers were assessed. The first brother
had DCM since 49 years old, ICD implantation at 51,
additional Pacemaker at 52. His neurological assessment
as well as CPK and EMG were normal at 53. His young
brother had also DCM since 38 years old and his neuro-
logical assessment was normal at 45. Muscle biopsy per-
formed in the oldest brother was considered as normal.
Emerin protein analysis on muscle by Western blot using
MANEM8 antibodies showed normal amounts while
emerin immunostaining studies on muscle cryosections
using NCL-Emerin antibodies showed complete absence
of emerin. Subsequent EMD gene analysis revealed a mis-
sense mutation within exon 1.
By using the UMD-EMD locus specific database
(http://www.umd.be/EMD/) gathering all published EMD
gene mutations as well as those found in LBGM (more
than 200 families), authors looked at EMD mutation
spectrum. It was found that truncating mutations leading
to absence or highly decreased emerin represent more
than 65% of probands, while non-truncating mutations,
including missense ones and leading to either absence or
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abnormal emerin, represents 21,5% of probands. The
remaining probands (13.5%) carry intronic mutations
with variable emerin amounts according to alternative
splicing. There are no clear phenotype/genotype correla-
tions due to high intra- and inter-familial variability.
Truncating mutations may lead to classical forms of
EDMD as well as severe forms with early ambulation loss
and moderate forms with benign skeletal muscle
involvement.
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